2016
DOI: 10.1021/acsinfecdis.6b00053
|View full text |Cite
|
Sign up to set email alerts
|

Antibacterial FabH Inhibitors with Mode of Action Validated in Haemophilus influenzae by in Vitro Resistance Mutation Mapping

Abstract: Fatty acid biosynthesis is essential to bacterial growth in Gram-negative pathogens. Several small molecules identified through a combination of high-throughput and fragment screening were cocrystallized with FabH (β-ketoacyl-acyl carrier protein synthase III) from Escherichia coli and Streptococcus pneumoniae. Structure-based drug design was used to merge several scaffolds to provide a new class of inhibitors. After optimization for Gram-negative enzyme inhibitory potency, several compounds demonstrated antim… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
40
0
3

Year Published

2017
2017
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 53 publications
(46 citation statements)
references
References 23 publications
3
40
0
3
Order By: Relevance
“…BioZ is a FabH (β-ketoacyl-ACP synthase) homologue and not an α/β-hydrolase. It has a catalytic Cys/His/Asn triad 47 , 48 . Thus, it is not able to cleave the methyl ester like BioH with its catalytic Ser.…”
Section: Resultsmentioning
confidence: 99%
“…BioZ is a FabH (β-ketoacyl-ACP synthase) homologue and not an α/β-hydrolase. It has a catalytic Cys/His/Asn triad 47 , 48 . Thus, it is not able to cleave the methyl ester like BioH with its catalytic Ser.…”
Section: Resultsmentioning
confidence: 99%
“…High quality crystallographic structures of target proteins of E.coli and S. aureus with good resolution were retrieved from Protein data bank (Fig. 2) [52] were selected to understand molecular interactions between nanoparticles and active pocket residues of protein.…”
Section: Molecular Docking Studymentioning
confidence: 99%
“…The two best characterized molecular targets are FabI and FabH, which have been subject to numerous discovery campaigns by a variety of investigators. One major recurring result from these campaigns is the difficulty in getting both spectrum and potency [9,21,99,104-107,123]. For example, a recent FabH discovery campaign reported a series of 22 thiolactomycin analogues and tested these analogues against Mycobacterium tuberculosis , Francisella tularensis , Yersinia pestis , and Staphylococcus aureus [99].…”
Section: Antibiotic Discovery In Bacterial Fatty Acid Metabolismmentioning
confidence: 99%